A Phase 3 trial averages $48 million and spans roughly 12 years from discovery to market approval. Regulatory and execution constraints shape whether results translate into approvals, including FDA review timelines, GCP compliance, and enrollment delays. This article compiles funding patterns, participant representation, and success rates to map the bottlenecks that repeatedly slow development.
Key Takeaways
- Average cost of a Phase 3 trial is $48 million, with total development cost per approved drug at $2.6 billion
- Industry sponsors fund 78% of trials, while NIH funds 12%, per 2022 ClinicalTrials.gov data
- FDA reviews 98% of IND applications within 30 days, with only 2% resulting in clinical hold in 2023
- The global average enrollment for Phase 3 trials is 1,256 participants, with a median primary endpoint duration of 18 months
- Women comprise 53% of participants in Phase 1 trials but only 41% in Phase 3 cardiology trials as of 2022
- Racial/ethnic minorities account for 22% of U.S. trial participants, with Black individuals at 5.2% despite being 13.6% of the population
- As of December 2023: June 2026, ClinicalTrials.gov lists 448,265 clinical studies from 231 countries, with 52,874 studies actively recruiting participants
- In 2022, the number of new interventional clinical trials registered on ClinicalTrials.gov increased by 12% compared to 2021, reaching 38,000 new trials
- Between 2000 and 2022, oncology trials accounted for 25% of all trials registered on ClinicalTrials.gov, totaling over 100,000 studies
- The probability of success from Phase 1 to approval is 8.3% for all indications, but 3.4% for oncology
- Phase 2 to Phase 3 transition success rate is 47% overall, dropping to 31% in neurology, as of 2022 data
- Of 5,000+ drugs entering Phase 1 annually, only 1 in 10 reaches market approval, per FDA 2023 analysis
- As of 2024, there are 7,846 Phase 1 trials registered worldwide on ClinicalTrials.gov, focusing primarily on novel therapies
- Phase 2 trials constitute 28% of all active trials, with an average duration of 2.3 years from first patient dosed to primary completion
- 62% of Phase 3 trials are randomized, controlled, and double-blind, compared to 45% in Phase 2
Phase 3 trials cost about $48M each, but approval depends on success rates, timelines, and costs shaped by regulation.
Related reading
01 · Category
Costs, Funding, and Regulation21 stats
01
Average cost of a Phase 3 trial is $48 million, with total development cost per approved drug at $2.6 billion
02
Industry sponsors fund 78% of trials, while NIH funds 12%, per 2022 ClinicalTrials.gov data
03
FDA reviews 98% of IND applications within 30 days, with only 2% resulting in clinical hold in 2023
04
Orphan drug designation granted to 45% of rare disease trials, reducing costs by 25% via incentives
05
Venture capital investment in biotech trials reached $52 billion in 2022, up 20% YoY
06
Regulatory approval timelines average 12 years from discovery to market, with 7 years in clinical phases
07
91% of trials comply with GCP standards per FDA audits in 2023, with violations in 9% leading to holds
08
EU EMA approves 55 new drugs annually, with fast-track for 22% of oncology submissions
09
Cost per patient in Phase 1 trials averages $25,000,escalating to $45,000 in Phase 3
10
Public-private partnerships funded 15% of COVID-19 trials, saving an estimated $10 billion in costs
11
IRB approval rates for amendments average 95%, with delays costing $500,000 per month in large trials
12
Phase 1 cost averages $4.5M, Phase 2 $15M, Phase 3 $150M per IQVIA 2023
13
Pharma sponsors 82% trials, academia 10%, per ClinicalTrials.gov 2023
14
FDA IND holds issued in 1.8% applications, resolved in 90% within 60 days
15
Orphan incentives cut Phase 3 costs by 30% for 500+ designations yearly
16
Biotech VC funding for trials: $48B in 2023, down 8% from 2022 peak
17
Total R&D spend by pharma: $200B annually, 20% on clinical trials
18
GCP violation rate 7% in FDA inspections, costing $1-5M per major finding
19
EMA PRIME scheme fast-tracks 120 drugs/year, cutting review by 4 months
20
Per-patient cost: $40K Phase 3 oncology vs. $20K infectious disease
21
Operation Warp Speed invested $18B, enabling 6 vaccines in <1 year
Interpretation
Costs, Funding, and Regulation Interpretation
Despite the astronomical price tags, labyrinthine regulatory hoops, and frequent investor jitters, the clinical trials machine grinds forward with a costly but often heroic tenacity, proving that getting a new drug from lab to pharmacy shelf is a financial odyssey worthy of both awe and a very stern accounting audit.
02 · Category
Enrollment and Participant Data19 stats
01
The global average enrollment for Phase 3 trials is 1,256 participants, with a median primary endpoint duration of 18 months
02
Women comprise 53% of participants in Phase 1 trials but only 41% in Phase 3 cardiology trials as of 2022
03
Racial/ethnic minorities account for 22% of U.S. trial participants, with Black individuals at 5.2% despite being 13.6% of the population
04
Pediatric trials (under 18 years) number 12,500 on ClinicalTrials.gov, representing 2.8% of all trials
05
In 2022, the average time to enroll 80% of Phase 3 trial participants was 19 months, delayed by 15% due to COVID-19
06
Elderly participants (65+) make up 34% of oncology trial enrollees, but only 19% in neurology trials
07
Decentralized trials enrolled 28% more diverse participants in 2023 compared to traditional site-based trials
08
Screen failure rates average 25% in Phase 2 trials, rising to 32% in rare disease studies
09
Patient retention rates in oncology Phase 3 trials averaged 82%, with dropout rates highest at 18% due to adverse events
10
Global trials enroll an average of 1,800 participants per study, with 45% from North America
11
U.S. trials enroll average 450 participants per Phase 2 study, 40% from community sites
12
Hispanics/Latinos represent 7.4% of trial participants despite 18% U.S. population share
13
Orphan disease trials enroll median 45 patients, with 65% single-country
14
Time to first patient enrollment averages 4.2 months for Phase 1, 6.8 for Phase 3
15
Gender imbalance: 72% male in ALS trials, 48% female in breast cancer
16
Wearables used in 22% of trials boosted enrollment by 35% in DCTs 2023
17
Dropout rates: 12% in Phase 1 (safety), 22% Phase 3 (efficacy failure)
18
Global median age of participants is 54 years, skewed by oncology at 62 years
19
Underserved rural participants: 8% of U.S. enrollees despite 19% population
Interpretation
Enrollment and Participant Data Interpretation
While our clinical trials reveal a heartening pivot toward diversity, the data confesses a sobering truth: the path to equitable and efficient research is still frustratingly obstructed by systemic enrollment biases, logistical delays, and a persistent disconnect between trial populations and the real-world communities they aim to serve.
03 · Category
Global Overview and Trends10 stats
01
As of December 2023: June 2026, ClinicalTrials.gov lists 448,265 clinical studies from 231 countries, with 52,874 studies actively recruiting participants
02
In 2022, the number of new interventional clinical trials registered on ClinicalTrials.gov increased by 12% compared to 2021, reaching 38,000 new trials
03
Between 2000 and 2022, oncology trials accounted for 25% of all trials registered on ClinicalTrials.gov, totaling over 100,000 studies
04
From 2018 to 2022, the annual growth rate of clinical trials in Asia was 8.5%, outpacing North America at 4.2%
05
In 2023, decentralized clinical trials (DCTs) represented 15% of all new trial initiations globally, up from 5% in 2019
06
In 2023, ClinicalTrials.gov lists 448,266 clinical studies from 231 countries, including 52,875 actively recruiting
07
New trials registered in 2023 totaled 42,100 on ClinicalTrials.gov, a 10.8% increase from 2022
08
Neurological disorders trials grew 15% annually from 2018-2023, reaching 45,000 studies
09
China registered 18,500 new trials in 2022, becoming the second-largest sponsor after the US
10
Digital health trials surged 300% since 2019, numbering 5,200 by 2023
Interpretation
Global Overview and Trends Interpretation
The global clinical research landscape is booming with unprecedented scale and diversity, as evidenced by a 12% surge in new trials last year, Asia's accelerating growth, and a tripling of digital health studies, yet it remains soberingly anchored by oncology's quarter-century dominance, reminding us that for all our innovation, cancer is still the relentless frontier.
More related reading
04 · Category
Outcomes and Efficacy20 stats
01
The probability of success from Phase 1 to approval is 8.3% for all indications, but 3.4% for oncology
02
Phase 2 to Phase 3 transition success rate is 47% overall, dropping to 31% in neurology, as of 2022 data
03
Of 5,000+ drugs entering Phase 1 annually, only 1 in 10 reaches market approval, per FDA 2023 analysis
04
Oncology drugs have a 5.1% LOA (likelihood of approval) from Phase 1, improved from 3.4% in 2010
05
72% of Phase 3 trials meet primary endpoints, but only 55% demonstrate statistical significance (p<0.05)
06
Rare disease trials show 12% higher success rates post-Phase 2 due to orphan drug incentives
07
COVID-19 vaccine trials achieved 95% efficacy in Phase 3, highest recorded for vaccines
08
Attrition rate from Phase 1 to 2 is 52%, primarily due to safety concerns (38%) and efficacy (29%)
09
Immuno-oncology trials have 2x higher Phase 3 success rates (25%) vs. traditional chemotherapy (12%)
10
The average time from Phase 3 completion to FDA approval is 10.6 months for priority review drugs
11
Overall LOA from Phase 1 to approval is 9.6% for non-oncology, 4.5% for immuno-oncology
12
Phase 3 success: 65% for vaccines, 38% for cell/gene therapies 2015-2022
13
Of 10,000 Phase 1 starts yearly, ~1,000 reach Phase 3, 100 approved (1%)
14
Cardiovascular drugs Phase 2 success 52%, highest among indications
15
Primary endpoint met in 71% Phase 3 trials, but regulatory approval in 58%
16
Gene therapy trials success rate 18% Phase 1 to approval, vs. 7% small molecules
17
mRNA vaccines Phase 3 efficacy averaged 92% in 2020 trials
18
Attrition: 70% fail before Phase 3, 30% in Phase 3 (efficacy 50%, safety 25%)
19
Alzheimer's trials Phase 2 success only 8%, lowest across diseases
20
Accelerated approvals based on surrogate endpoints succeed in confirmatory trials 75% time
Interpretation
Outcomes and Efficacy Interpretation
Navigating drug development is like crossing a minefield with a metal detector that mostly beeps for false alarms, where even a celebrated 95% vaccine efficacy is a stark reminder that your oncology drug still faces a 95% chance of oblivion.
05 · Category
Phase and Design Statistics20 stats
01
As of 2024, there are 7,846 Phase 1 trials registered worldwide on ClinicalTrials.gov, focusing primarily on novel therapies
02
Phase 2 trials constitute 28% of all active trials, with an average duration of 2.3 years from first patient dosed to primary completion
03
62% of Phase 3 trials are randomized, controlled, and double-blind, compared to 45% in Phase 2
04
Adaptive trial designs were used in 18% of oncology Phase 2/3 trials initiated in 2022, up from 10% in 2018
05
Basket trials, targeting multiple tumor types with one drug, made up 4.2% of all oncology trials in 2023
06
Umbrella trials, evaluating multiple drugs in one tumor type, comprised 3.8% of precision medicine trials registered in 2022
07
The average number of arms in Phase 3 trials increased from 2.1 in 2010 to 2.8 in 2022
08
In 2023, 41% of new trials incorporated real-world evidence (RWE) endpoints alongside traditional ones
09
Master protocols were utilized in 7% of COVID-19 related trials during 2020-2022
10
Single-arm trials represent 22% of Phase 2 oncology studies, versus 5% in non-oncology
11
Phase 1 trials average 27.3 months from FPFV to LPLV globally, per 2022 data
12
35% of Phase 2 trials are multicenter, involving average 25 sites across 3 countries
13
Seamless Phase 2/3 designs used in 12% of new trials in 2023, reducing timeline by 18 months
14
Platform trials accounted for 9% of adaptive designs in infectious diseases post-COVID
15
68% of Phase 3 trials use surrogate endpoints for accelerated approval
16
N-of-1 trials, individualized designs, number 1,200 for rare diseases on ClinicalTrials.gov
17
Blinding rates: 78% double-blind in Phase 3 vs. 52% single-blind in Phase 1
18
Enrichment designs in Phase 2 increased to 22% for precision medicine in 2022
19
Crossover designs used in 14% of Phase 2 neurology trials
20
Average Phase 3 trial has 4.2 endpoints, with 1.8 secondary, per IQVIA 2022
Interpretation
Phase and Design Statistics Interpretation
Nearly 8,000 early-phase ventures hint at our desperate hope for novel cures, while the growing complexity of later trials—with more arms, adaptive designs, and real-world data—reveals our equally desperate scramble to prove they actually work.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Karl Becker. (2026, February 13). Clinical Trials Statistics. Gitnux. https://gitnux.org/clinical-trials-statistics
MLA
Karl Becker. "Clinical Trials Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/clinical-trials-statistics.
Chicago
Karl Becker. 2026. "Clinical Trials Statistics." Gitnux. https://gitnux.org/clinical-trials-statistics.
Sources & references
17 datasets cited across this report · attribution is report-level